Preferential incorporation of eicosanoid precursor fatty acids into human umbilical vein endothelial cell phospholipids.
We have examined the preferential incorporation of specific fatty acids into phospholipid classes of cultured human umbilical vein endothelial cells. Pulse-labeling of human umbilical vein endothelial cell phospholipids with radiolabeled fatty acids and inhibition of radiolabeled fatty acid incorporation by competition with excess, unlabeled fatty acids in pair-wise combinations revealed two distinct classes of esterification systems into human umbilical vein endothelial cell phospholipids. The eicosanoid precursor fatty acids, including arachidonate, 8,11,14-eicosatrienoate (ETA) and 5,8,11,14,17-eicosapentaenoate (EPA), exhibited high affinity incorporation into total phospholipids, whereas other fatty acids, including docosahexaenoate and monohydroxy eicosatetraenoates, showed low affinity incorporation. The relative degree of incorporation of eicosanoid precursor fatty acids into phospholipid classes was phosphatidylcholine (PC) greater than phosphatidylethanolamine (PE) greater than phosphatidylinositol (PI) greater than phosphatidylserine (PS). The specific activity of [14C]arachidonic acid-labeled PI was two times higher than that of any other radiolabeled phospholipids. When competitive incorporation of eicosanoid precursor fatty acids into phospholipid classes was studied, they were found to be acylated into different phospholipid classes at different rates. Although eicosanoid precursor fatty acids were not preferentially incorporated into PC, arachidonic acid was preferentially incorporated into the other phospholipids and exhibited particular selectivity in comparison with the other eicosanoid precursor fatty acids for incorporation into PI. These results demonstrate that human umbilical vein endothelial cells possess selective incorporation mechanisms for specific fatty acids into various phospholipids via the deacylation-reacylation pathway.
Takayama
H
H
Department of Medicine, Brigham and Women's Hospital, Boston, MA 02115.
Gimbrone
M A
MA
Schafer
A I
AI
D015126:8,11,14-Eicosatrienoic Acid / Q000378:metabolism; D004281:Docosahexaenoic Acids / Q000378:metabolism; D004537:Eicosanoic Acids / Q000378:metabolism*; D015118:Eicosapentaenoic Acid / Q000378:metabolism; D004730:Endothelium, Vascular / Q000378:metabolism*; D005227:Fatty Acids / Q000378:metabolism*; D006801:Humans; D006893:Hydroxyeicosatetraenoic Acids / Q000378:metabolism; D010743:Phospholipids / Q000378:metabolism*; D014471:Umbilical Veins / Q000378:metabolism
D004537:Eicosanoic Acids; D005227:Fatty Acids; D006893:Hydroxyeicosatetraenoic Acids; D010743:Phospholipids; D004281:Docosahexaenoic Acids; C022022:5-hydroxy-6,8,11,14-eicosatetraenoic acid; D015118:Eicosapentaenoic Acid; D015126:8,11,14-Eicosatrienoic Acid